Shanghai Bao Pharmaceuticals Receives Clinical Trial Approval for New Indication of KJ101

Key Highlights

• Shanghai Bao Pharmaceuticals Co., Ltd. has announced that its leading product, KJ101 (recombinant human chymotrypsin), has received approval from the National Medical Products Administration (NMPA) of China to conduct clinical trials for a new indication – the dissolution and removal of gastric mucus during gastroscopy.
• KJ101 is developed using synthetic biology and recombinant yeast fermentation technology, making it a high-purity, animal-free alternative to traditional chymotrypsin products.
• The company emphasizes that KJ101’s unique production process not only ensures consistent quality but also eliminates the risk of contamination from animal-derived viruses and allergenicity, addressing concerns associated with animal-based products.
• For wound-healing indications (burns, trauma, surgical incisions, pressure ulcers, diabetic foot ulcers), KJ101 already received IND approval from NMPA in February 2025, and a Phase II clinical trial commenced in July 2025.

Detailed Analysis & Potential Price-Sensitive Information

The approval to initiate clinical trials for KJ101 in the field of gastroenterology is a significant milestone for Shanghai Bao Pharmaceuticals.
Chymotrypsin has a long-standing position in the clinical management of wound debridement, pus liquefaction, and removal of necrotic tissue, and is used across numerous specialties such as respiratory medicine, surgery, ENT, gynecology, pediatrics, dentistry, ophthalmology, dermatology, gastroenterology, and anorectal surgery. The new indication specifically targets the removal of gastric mucus during gastroscopy, aiming to improve procedural visibility and patient outcomes.

KJ101’s recombinant technology sets it apart from traditional animal-derived chymotrypsin:

• It offers high purity and consistency due to the absence of variability tied to animal raw materials or livestock industry fluctuations.
• There is no risk of contamination by animal-origin viruses or allergenicity, which enhances clinical safety and regulatory acceptance.
• The manufacturing process is scalable and can support mass production, an important factor for commercial viability and supply chain resilience.

The company’s ongoing efforts with KJ101 also include IND approval for several types of wound healing, with a Phase II clinical trial already underway. This demonstrates the company’s commitment to expanding the clinical utility and commercial potential of KJ101 beyond a single indication.

Risks and Considerations for Shareholders

• The company explicitly states that there is no guarantee of ultimate success in the development or commercialization of KJ101. There are unpredictable factors in the clinical trial process, including trial results, timing, regulatory evaluations, and approvals, all of which are subject to uncertainty.
• Shareholders and potential investors are advised to exercise caution as the outcomes of clinical development could materially affect the value and prospects of the company’s shares.

Leadership and Board Composition

The announcement is signed by Dr. Liu Yanjun, Chairman of the Board and Executive Director. The Board comprises a mix of executive, non-executive, and independent non-executive directors, reflecting a diverse leadership structure.

Conclusion

Why this matters: The approval to initiate clinical trials for a new indication of KJ101 could be a price-sensitive event, as successful development and commercialization of this product have the potential to expand Shanghai Bao Pharmaceuticals’ market share and revenue streams. The novel recombinant approach addresses long-standing issues with animal-derived enzymes, positioning KJ101 as a potentially disruptive product in the biotechnology and pharmaceutical landscape.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult professional advisors before making investment decisions. The success of clinical trials and regulatory approvals cannot be guaranteed.

View BAO PHARMA-B Historical chart here